- Trials with a EudraCT protocol (135)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
135 result(s) found for: Brain Chemistry.
Displaying page 1 of 7.
EudraCT Number: 2005-005707-42 | Sponsor Protocol Number: A090624 | Start Date*: 2007-07-23 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | |||||||||||||
Full Title: A single centre phase II study of Interleukin 1 receptor antagonist in the treatment of severe Traumatic Brain Injury | |||||||||||||
Medical condition: Severe Traumatic Brain Injury | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006694-39 | Sponsor Protocol Number: ASF-CP02-001 | Start Date*: 2022-07-08 | ||||||||||||||||
Sponsor Name:Lantmännen Medical AB | ||||||||||||||||||
Full Title: An open-label, historical cohort control study to evaluate the safety and tolerability of AF-16 in patients with cerebral oedema caused by traumatic brain injury (TBI) | ||||||||||||||||||
Medical condition: Cerebral oedema caused by traumatic brain injury (TBI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014545-83 | Sponsor Protocol Number: C10953/3067/ES/MN | Start Date*: 2010-02-24 | ||||||||||||||||
Sponsor Name:Cephalon Inc. | ||||||||||||||||||
Full Title: A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients wi... | ||||||||||||||||||
Medical condition: Patients with excessive Sleepiness associated with mild or moderate closed Traumatic Brain Injury (TBI) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001119-30 | Sponsor Protocol Number: 2B3-101-CR-001 | Start Date*: 2011-06-22 | |||||||||||||||||||||||||||||||
Sponsor Name:to-BBB technologies B.V. | |||||||||||||||||||||||||||||||||
Full Title: An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma. | |||||||||||||||||||||||||||||||||
Medical condition: Solid tumors and brain metastases or recurrent malignant glioma, HER2-positive adenocarcinoma of the breast with brain metastases | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014544-11 | Sponsor Protocol Number: C10953/3069/ES/MN | Start Date*: 2010-05-21 | ||||||||||||||||
Sponsor Name:Cephalon Inc | ||||||||||||||||||
Full Title: Estudio abierto de 12 meses para la evaluación de la seguridad, la tolerabilidad y la eficacia de armodafinil (150 mg/día y 250 mg/día) como tratamiento para pacientes con somnolencia excesiva asoc... | ||||||||||||||||||
Medical condition: Pacientes con somnolencia excesiva asociada a un trauma craneo-cerebral no penetrante leve o moderado. Excessive sleepiness accociated with mild or moderate closed traumatic brain injury | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-004252-40 | Sponsor Protocol Number: CEPO906A2209 | Start Date*: 2005-09-05 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer | ||
Medical condition: Non-small cell lung cancer (NSCLC) - patients with inoperable stage IIIb or IV NSCLC have a very poor prognosis, with overall survival of 4-8 months. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004007-12 | Sponsor Protocol Number: 066VER | Start Date*: 2020-06-02 |
Sponsor Name:University of Sussex | ||
Full Title: Brain connectivity and patient reported outcomes in people with HIV (PWH) with symptoms of insomnia switching integrase inhibitor-based ART; a randomised controlled study | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000758-37 | Sponsor Protocol Number: NO18517 | Start Date*: 2016-08-23 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | ||||||||||||||||||
Full Title: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas | ||||||||||||||||||
Medical condition: High Grade Glioma Brainstem Glioma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001684-21 | Sponsor Protocol Number: NV1205-009 | Start Date*: 2018-04-20 |
Sponsor Name:Neurov Acquisition LLC | ||
Full Title: Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD) | ||
Medical condition: Childhood Cerebral Adrenoleukodystrophy (CCALD) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: GB (Prematurely Ended) FR (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2014-004483-38 | Sponsor Protocol Number: TMP001_MS | Start Date*: 2015-07-16 | |||||||||||
Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) | |||||||||||||
Full Title: TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial | |||||||||||||
Medical condition: Patients with defined diagnosis of relapsing-remitting multiple sclerosis and at least 1 documented relapse during the previous year OR at least 2 documented relapses during the previous 2 years. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003114-13 | Sponsor Protocol Number: 1 | Start Date*: 2012-12-07 |
Sponsor Name:West Hertfordshire Hospitals NHS Trust | ||
Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in mechanically ventilated patients at high risk of delirium | ||
Medical condition: Delirium | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019162-83 | Sponsor Protocol Number: Y5252120148 | Start Date*: 2011-06-07 | |||||||||||
Sponsor Name:Ipsen Innovation | |||||||||||||
Full Title: A phase III, multicentre, prospective, open label extension study to assess the long term safety and efficacy of repeated treatment of Dysport intramuscular injections used for the treatment of upp... | |||||||||||||
Medical condition: Arm spasticity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) SK (Completed) PL (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000046-31 | Sponsor Protocol Number: Omega18-13-03 | Start Date*: 2011-11-29 |
Sponsor Name:The Sahlgrenska Center for Pediatric Ophtalmology Research | ||
Full Title: A randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum in preventing Retinopathy of Prematurity | ||
Medical condition: Premature male/female infants, <28 gestational weeks at birth with risk of developing retinopathy of prematurity (ROP) | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-010922-21 | Sponsor Protocol Number: B2571007(3134K1-2203-EU) | Start Date*: 2009-09-18 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA | |||||||||||||
Full Title: A phase II a , Multicenter, Randomized , Third -party Unblinded , Long- term Extension study to Determine Safety, Tolerability and Immunogenicity of ACC-001 with QS-21 Adjuvant in Subjects with Mil... | |||||||||||||
Medical condition: Patients with mild to moderate Alzheimer's disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019765-28 | Sponsor Protocol Number: SP0993 | Start Date*: 2011-02-08 | |||||||||||
Sponsor Name:UCB BIOSCIENCES GmbH | |||||||||||||
Full Title: A MULTICENTER, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, POSITIVE CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) TO CONTROLLED RELEASE CARBAMAZEPINE (400 TO 1200M... | |||||||||||||
Medical condition: Epilepsy, partial onset or generalised tonic-clonic seizures. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) FI (Completed) SE (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed) SK (Completed) GB (Completed) GR (Completed) IT (Completed) LV (Completed) LT (Completed) BG (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001109-22 | Sponsor Protocol Number: PBGM01-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:Passage Bio, Inc. | ||
Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Su... | ||
Medical condition: GM1 gangliosidosis (GM1) is an autosomal recessive disorder that results from mutations in the human galactosidase beta 1 gene (GLB1), which encodes beta-galactosidase (β-gal). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002605-65 | Sponsor Protocol Number: DOTA2013/DOTATER | Start Date*: 2013-11-26 |
Sponsor Name:Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS | ||
Full Title: Radioreceptor therapy with labeled somatostatin analogues in tumors with high expression of somatostatin receptors. | ||
Medical condition: Patients with tumors expressing somatostatin receptors. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005549-39 | Sponsor Protocol Number: EHT 0202/002 | Start Date*: 2007-12-19 | |||||||||||
Sponsor Name:EXONHIT | |||||||||||||
Full Title: A pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIa study to determine the clinical safety/tolerability and exploratory efficacy of EHT 0202 (40 and 80 mg ... | |||||||||||||
Medical condition: Alzheimer disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003176-39 | Sponsor Protocol Number: 205MS303 | Start Date*: 2013-05-31 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Prematurely Ended) CZ (Completed) HU (Completed) PL (Completed) SE (Completed) ES (Completed) IE (Prematurely Ended) GB (Completed) FI (Prematurely Ended) GR (Completed) FR (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002685-23 | Sponsor Protocol Number: ICT-107-301 | Start Date*: 2016-08-19 | |||||||||||
Sponsor Name:ImmunoCellular Therapeutics, Ltd. | |||||||||||||
Full Title: A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy. | |||||||||||||
Medical condition: Treatment of newly diagnosed glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.